These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38485644)

  • 1. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
    Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
    Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology: Rare Biopsy Cases Lacking Associated Invasive High-grade Carcinoma.
    Russell DH; Epstein JI
    Am J Surg Pathol; 2022 Feb; 46(2):233-240. PubMed ID: 34619708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
    BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical cribriform lesions of the prostate: clinical significance, differential diagnosis and current concept of intraductal carcinoma of the prostate.
    Shah RB; Zhou M
    Adv Anat Pathol; 2012 Jul; 19(4):270-8. PubMed ID: 22692290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma.
    Shah RB; Yoon J; Liu G; Tian W
    Histopathology; 2017 Nov; 71(5):693-702. PubMed ID: 28570007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Taylor AS; Morgan TM; Wallington DG; Chinnaiyan AM; Spratt DE; Mehra R
    Prostate; 2020 Feb; 80(2):146-152. PubMed ID: 31737920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
    Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
    Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Understanding and Management of Intraductal Carcinoma of the Prostate.
    Considine B; Adeniran A; Hurwitz ME
    Curr Oncol Rep; 2021 Jul; 23(9):110. PubMed ID: 34272624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate.
    Bettendorf O; Schmidt H; Staebler A; Grobholz R; Heinecke A; Boecker W; Hertle L; Semjonow A
    Genes Chromosomes Cancer; 2008 Jul; 47(7):565-72. PubMed ID: 18383208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular complexity of intraductal carcinoma of the prostate.
    Zhu S; Xu N; Zeng H
    Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
    Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
    J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
    Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P).
    Zhu S; Zhao J; Nie L; Yin W; Zhang Y; Zhao F; Ni Y; Zhang X; Wang Z; Dai J; Liu Z; Chen J; Zeng Y; Wang Z; Sun G; Liang J; Zhao X; Zhu X; Tao R; Yang J; He B; Chen N; Shen P; Zeng H
    BMC Med; 2022 Jul; 20(1):237. PubMed ID: 35864546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion.
    Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY
    Hum Pathol; 2014 Aug; 45(8):1572-81. PubMed ID: 24842280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.
    Han B; Suleman K; Wang L; Siddiqui J; Sercia L; Magi-Galluzzi C; Palanisamy N; Chinnaiyan AM; Zhou M; Shah RB
    Am J Surg Pathol; 2010 Apr; 34(4):478-85. PubMed ID: 20220513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
    BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.